Risk Intelligence
Raw material price volatility
View Risks →Innova Captab delivered a strong Q4 FY26 with revenue of INR 448 cr (+42% YoY) and full-year revenue of INR 1,630 cr (+31% YoY), driven by broad-based growth across CDMO (+24% to INR 1,133 cr) and branded generics (+51% to INR 497 cr).
✓ Verified against BSE filing
Innova Captab delivered a strong Q4 FY26 with revenue of INR 448 cr (+42% YoY) and full-year revenue of INR 1,630 cr (+31% YoY), driven by broad-based growth across CDMO (+24% to INR 1,133 cr) and branded generics (+51% to INR 497 cr). The Jammu facility contributed ~INR 300 cr in FY26 and is nearing breakeven, with management expecting margin expansion as utilization ramps. EBITDA margin for FY26 was 15.4%, down ~60bps YoY due to product mix, but management guided for EBITDA growth to outpace revenue growth in FY27. PAT grew 10% to INR 140.9 cr, with depreciation and interest costs largely fixed. Key risks include raw material price volatility from geopolitical tensions and potential margin pressure from new capex at Baddi. Overall, the company is well-positioned to sustain 20%+ revenue growth with improving profitability.
Raw material price volatility
View Risks →Full transcript text is available on this route.
Read Transcript →CDMO segment grew driven by new customers and deeper wallet share.
Strong growth from geographical expansion and deeper penetration.
Jammu facility nearing breakeven; expected to contribute positively in FY27.
Expanded customer base to over 350 clients, including leading pharma companies.
Management expects to maintain 20%+ revenue growth driven by capacity ramp-up, product portfolio expansion, and market penetration.
Geopolitical tensions have led to an uptick in API and raw material prices, which could pressure margins if not fully passed on.
View Risks →